Literature DB >> 28527106

A Trans-acting Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal.

Miguel Alves-Ferreira1,2, Teresa Coelho3, Diana Santos1,2, Jorge Sequeiros1,2, Isabel Alonso1,2, Alda Sousa1,2, Carolina Lemos4,5,6.   

Abstract

Although all familial amyloid polyneuropathy (FAP) ATTRV30M patients carry the same causative mutation, early (<40) and late-onset forms (≥50 years) of FAP may coexist in the same family. However, this variability in age at onset is still unexplained. To identify modifiers closely linked to the TTR locus that may in part be associated with age at onset of FAP ATTRV30M, in particular in a group of very early-onset patients (≤30 years) when compared with late-onset individuals. A clinical genetic study at a referral center comprising a sample of 910 Portuguese individuals includes 589 Val30Met carriers, 102 spouses, and 189 controls from the general population. Haplotype analysis was performed, using eight intragenic single nucleotide polymorphisms (SNPs) at the TTR locus. We compared haplotypes frequency in FAP samples and controls and in parent-offspring pairs using appropriated statistical analysis. Haplotype A was the most common in the general population. Noteworthy, haplotype C was more frequent in early-onset (<40) than in late-onset patients (≥50 years) (p = 0.012). When comparing allelic frequencies of each SNP within haplotype C between "very early" (≤30 years) and late-onset (≥50 years) cases, the A allele of rs72922947 was associated with an earlier onset (p = 0.009); this remained significant after a permutation-based correction. Also, the heterozygous genotype (GA) for this SNP was associated with a decrease in mean age at onset of 8.6 years (p = 0.014). We found a more common haplotype (A) linked to the Val30Met variant and a possible modulatory trans effect on age at onset. These findings may lead to potential therapeutical targets.

Entities:  

Keywords:  Age at onset; Familial amyloid polyneuropathy (FAP); Haplotype; Trans effect; Transthyretin (TTR); Transthyretin-related amyloidosis

Mesh:

Substances:

Year:  2017        PMID: 28527106     DOI: 10.1007/s12035-017-0593-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  25 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M.

Authors:  Carolina Lemos; Teresa Coelho; Miguel Alves-Ferreira; Ana Martins-da-Silva; Jorge Sequeiros; Denisa Mendonça; Alda Sousa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-09-17       Impact factor: 10.154

3.  Haplotype analysis of familial amyloidotic polyneuropathy. Evidence for multiple origins of the Val----Met mutation most common to the disease.

Authors:  K Yoshioka; H Furuya; H Sasaki; M J Saraiva; P P Costa; Y Sakaki
Journal:  Hum Genet       Date:  1989-04       Impact factor: 4.132

4.  Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence.

Authors:  A Sousa; R Andersson; U Drugge; G Holmgren; O Sandgren
Journal:  Hum Hered       Date:  1993 Sep-Oct       Impact factor: 0.444

5.  Pathogenesis of transthyretin amyloidosis.

Authors:  Merrill D Benson
Journal:  Amyloid       Date:  2012-03-27       Impact factor: 7.141

6.  is-rSNP: a novel technique for in silico regulatory SNP detection.

Authors:  Geoff Macintyre; James Bailey; Izhak Haviv; Adam Kowalczyk
Journal:  Bioinformatics       Date:  2010-09-15       Impact factor: 6.937

7.  In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis.

Authors:  Renato Polimanti; Marco Di Girolamo; Dario Manfellotto; Maria Fuciarelli
Journal:  Amyloid       Date:  2014-04-29       Impact factor: 7.141

Review 8.  Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain).

Authors:  Miguel Munar-Qués; Maria J M Saraiva; Carlos Viader-Farré; José María Zabay-Becerril; Juana Mulet-Ferrer
Journal:  Amyloid       Date:  2005-03       Impact factor: 7.141

9.  Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden.

Authors:  Miguel Luz Soares; Teresa Coelho; Alda Sousa; Gösta Holmgren; Maria João Saraiva; Daniel L Kastner; Joel N Buxbaum
Journal:  Eur J Hum Genet       Date:  2004-03       Impact factor: 4.246

10.  On the origin of the transthyretin Val30Met familial amyloid polyneuropathy.

Authors:  C Zaros; E Genin; U Hellman; M A Saporta; L Languille; M Wadington-Cruz; O Suhr; M Misrahi; V Planté-Bordeneuve
Journal:  Ann Hum Genet       Date:  2008-05-05       Impact factor: 1.670

View more
  10 in total

Review 1.  Transthyretin familial amyloid polyneuropathy: an update.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2017-12-16       Impact factor: 4.849

2.  Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.

Authors:  Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Hum Genet       Date:  2019-10-29       Impact factor: 4.132

3.  Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.

Authors:  David Adams; Vincent Algalarrondo; Michael Polydefkis; Nitasha Sarswat; Michel S Slama; Jose Nativi-Nicolau
Journal:  Orphanet J Rare Dis       Date:  2021-10-03       Impact factor: 4.123

4.  Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis.

Authors:  Intissar Anan; Ole B Suhr; Katarzyna Liszewska; Jorge Mejia Baranda; Björn Pilebro; Jonas Wixner; Elisabet Ihse
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

5.  Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria.

Authors:  Teodora Chamova; Mariana Gospodinova; Ognian Asenov; Tihomir Todorov; Zornitsa Pavlova; Andrey Kirov; Sylvia Cherninkova; Kristina Kastreva; Ani Taneva; Stanislava Blagoeva; Sashka Zhelyazkova; Plamen Antimov; Kaloian Chobanov; Albena Todorova; Ivailo Tournev
Journal:  Front Neurol       Date:  2022-04-08       Impact factor: 4.003

6.  High Hereditary Transthyretin-Related Amyloidosis Prevalence in Crete: Genetic Heterogeneity and Distinct Phenotypes.

Authors:  Minas Tzagournissakis; Emmanouil Foukarakis; Dimitrios Samonakis; Miltiadis Tsilimbaris; Kleita Michaelidou; Lambros Mathioudakis; Anastasios Marinis; Emmanouil Giannakoudakis; Cleanthe Spanaki; Irene Skoula; Sofia Erimaki; Georgios Amoiridis; Georgios Koutsis; Sofia Koukouraki; Kostas Stylianou; Andreas Plaitakis; Panayiotis D Mitsias; Ioannis Zaganas
Journal:  Neurol Genet       Date:  2022-09-09

7.  Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden.

Authors:  Juan González-Moreno; Aina Gaya-Barroso; Inés Losada-López; Adrián Rodríguez; Teresa Bosch-Rovira; Tomás Ripoll-Vera; Mercedes Usón; Antoni Figuerola; Cristina Descals; Carles Montalà; María Asunción Ferrer-Nadal; Eugenia Cisneros-Barroso
Journal:  Orphanet J Rare Dis       Date:  2021-06-10       Impact factor: 4.123

8.  Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis.

Authors:  Antonella De Lillo; Gita A Pathak; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Federico Perfetto; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Clin Epigenetics       Date:  2020-11-17       Impact factor: 6.551

9.  Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Authors:  Márcia Waddington-Cruz; Jonas Wixner; Leslie Amass; Jan Kiszko; Doug Chapman; Yukio Ando
Journal:  Neurol Ther       Date:  2021-05-22

10.  A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.

Authors:  Juan González-Moreno; Inés Losada-López; Eugenia Cisneros-Barroso; Pablo Garcia-Pavia; José González-Costello; Francisco Muñoz-Beamud; Josep Maria Campistol; Roberto Fernandez-Torron; Doug Chapman; Leslie Amass
Journal:  Neurol Ther       Date:  2021-07-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.